Patients in PREFER: Partners and advisors

Our patient partners play a central role, making sure the patient perspective is present at all levels in the PREFER project.

The PREFER consortium includes four patient organisation: the European Cancer Patients Coalition (ECPC), Muscular Dystrophy UK (MDUK), European Patients Forum (EPF), and International Alliance of Patients’ Organizations (IAPO). Together they form the PREFER Patient Advisory Group, coordinated by ECPC.

Patient Advisory Group members are directly involved in activities within all work packages of PREFER, sharing common expectations and ensuring that the methodologies identified correspond to the patient views, experiences and preferences. We also have a number of individual patients with rheumatoid arthritis on board through the clinical research partners at the University of Birmingham.

PATIENT ADVISORY GROUP COMPOSITION

Coordinator: ECPC

  • European Cancer Patients Coallition (ECPC)
  • Muscular Dystrophy UK (MDUK)
  • European Patients Forum (EPF)
  • International Alliance of Patients’ Organizations (IAPO)

Contact the patient advisory group

The PREFER patient advisory group consists of four patient organisation: the European Cancer Patients Coallition (ECPC), who coordinates the work, Muscular Dystrophy UK (MDUK), European Patients Forum (EPF), and International Alliance of Patients’ Organizations (IAPO).

Antonella Cardone, ECPC

Charis Chirvalaki, ECPC

Kathi Apostolidis, ECPC

Juan José Ventura, ECPC

Valentina Strammielloas, EPF

Ziede Burage, IAPO

Jenny Sharpe, MDUK

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).